Presentations
The First International Conference On Single-Cell And Spatial Omics is held in Guangzhou, China: the Golden Age of Single Cell Analysis
GUANGZHOU, China, May 8, 2023 /PRNewswire/ -- On April 16th 2023, the first International Conference on Single-cell and Spatial Omics (TICSSO-1) has come to a grand conclusion.
Neuboron Medical Group and Xiamen Humanity Hospital Make ‘Grand Debut’ at Xiamen BNCT Tech Forum to Drive Clinical Application and New Drug Development
NANJING, China--(BUSINESS WIRE)-- On April 22, Neuboron Medical Group (NMG), a leading global Accelerator-based Boron Neutron Capture Therapy (AB-BNCT) total solution provider, and Xiamen Humanity Hospital (XHH) collaborated to co-host the Xiamen BNCT Technology Forum 2023 at the BNCT center in XHH.
Transcenta to Present Two Clinical Trial Progress at ASCO 2023
SUZHOU, China, May 8, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that two posters for clinical trials of its ADCC enhanced anti-CLDN18.2 monoclonal antibody Osemitamab (TST001) in combination with CAPOX or CAPOX plus Nivolumab for first-line G/GEJ cancer will be presented at 2023 American Society of Clinical Oncology ("ASCO") Annual Meeting.
Biosion Presents Discovery and Development Data at PEGS for its Anti-CD40 Agonistic Antibody
NEWARK, Del. and NANJING, China, May 8, 2023 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global R&D biotechnology company, today announced the upcoming presentation of discovery and development data for BSI-038, an anti-CD40 agonistic antibody at the PEGS Boston conference to be held from May 15 to 19, 2023.
HuidaGene Therapeutics Announces 19 Presentations Highlighting Advances in its Gene Therapy Technology Platforms at the 2023 ASGCT Annual Meeting
HuidaGene Therapeutics (辉大基因; HuidaGene), a global clinical-stage genome-editing company focused on developing CRISPR-based programmable genomic medicine, today announced nineteen (19) presentations on Company's various gene replacement and gene-editing platforms to unlock the full potential of genome medicines at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting taking place in Los Angeles from May 16-20, 2023.
Skyline Therapeutics to Present at the ASGCT 26th Annual Meeting
Skyline Therapeutics, an innovation-driven gene therapy company dedicated to developing unique and novel solutions to address unmet needs in rare and severe diseases, today announced multiple data presentations at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting in Los Angeles, CA, May 16-20, 2023.
CANbridge-UMass Chan Medical School Spinal Muscular Atrophy Gene Therapy Animal Data to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
CANbridge Pharmaceuticals Inc. (HKEX:1228), a leading China-based global biopharmaceutical company committed to the research, development and commercialization of transformative rare disease and rare oncology therapies, announced that data on the novel second-generation gene therapy, developed under the CANbridge and UMass Chan Medical School research agreement, will be presented at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, May 16-20, Los Angeles, CA.
